In the cancer patient group, there was a reduction in IL-4 (prostate: p = 0.001, HNSCC: p = 0.045, gastric: p = 0.046), IL-17 (prostate: p = 0.034, HNSCC: p = 0.001, gastric: p = 0.004), and IL-1β (prostate: p = 0.012, gastric: p = 0.049), and an increase in TGF-β for this group (prostate: p = 0.001 and gastric: p = 0.001). Here, IL17A is linked to cancer.